Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
IDENTIFIER (ClinicalTrials.gov):Ā NCT06041516
DRUG/TREATMENT: ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm.
PHASE: First-in-Human Phase I Trial
STATUS: Recruiting
SPONSOR: National Cancer Institute (NCI)
DESCRIPTION:
This is a first in human phase 1 study to testĀ a new drug, ADCT-701, in people with Neuroendocrine neoplasms (NENs).Ā
ADCT-701 is an antibody drug conjugate (or ADC) that specifically targets "Delta Like Non-CanonicalĀ Notch Ligand 1" or DLK1, an antigen which has recently been foundĀ to be expressed on neuroendocrine cancers. TheĀ hope is this drug willĀ suppress tumor growth,Ā shrink tumors after tumor growth,Ā and improveĀ survival.Ā
*Note: This study includes all neuroendocrineĀ neoplasms including neuroendocrine tumors, neuroendocrine carcinomas (i.e. "high grade neuroendocrine cancers"), pheochromocytoma, paraganglioma and adrenocortical carcinoma (ACC).Ā
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
CONTACT:
National Cancer Institute Medical Oncology
Kimberley J Cooper
EMAIL: kimberley.cooper@nih.gov
PHONE: 240-858-5798
Principal investigator: Jaydira Del Rivero, M.D.,National Cancer Institute (NCI)
LOCATIONS:
National Instititues of Health Clinical Center: Bethesda, Maryland, United States 20892